Copyright © 2019 Qrono Inc.  

 All Rights Reserved.

Milestone-focused Leadership Team

Sam Rothstein, PhD

 

Chief Executive Officer and Co-Founder of Qrono Inc.

Sam Rothstein is the lead inventor of Qrono’s Eloquent™ cancer therapy platform and a company co-founder.  He brings more than 12 years of experience in the design of complex drug products and has led $4 million of Small Business Innovation Research projects on their development.  At Qrono, Dr. Rothstein works closely with Dr. Little and Dr. Ferris to identify clinical needs and create matching cancer therapies.  Prior to becoming Qrono’s CEO in 2017, he served as the company’s CSO. In this role, he worked with FDA scientists to develop bio-equivalence guidance for long acting injections.  Dr. Rothstein holds chemical engineering degrees from Bucknell University and the University of Pittsburgh. 

Steven Little, PhD

 

Head of Qrono Scientific Advisory Board and Co-Founder

Steven Little is a Qrono co-founder and brings more than 20 years of expertise in immunoengineering.  He received his doctorate from the Massachusetts Institute of Technology's prestigious Langer Lab and has gone on to found two pharmaceutical spinouts in addition to Qrono Inc.  At the University of Pittsburgh, his research focuses on the development of drug products that mimic and change the body’s own signals during inflammation and healing.  Dr. Little is the Chairman of the Department of Chemical and Petroleum Engineering and is the William Kepler Whiteford Endowed Professor in the Departments of Bioengineering, Immunology, and Ophthalmology.

Robert Ferris, MD PhD

 

Head of Qrono Clinical Advisory Board 

Dr. Robert Ferris is Director of the UPMC Hillman Cancer Center (HCC), an associate vice-chancellor of cancer research, and a professor of oncology, otolaryngology, immunology, and radiation oncology at the University of Pittsburgh School of Medicine. As co-chair of the National Clinical Trials Network for head and neck cancer, Dr. Ferris has led more than 12 clinical trials focused on bringing novel cancer immunotherapies to patients.  At UPMC's HCC, Dr. Ferris also leads an active research program linking cancer outcomes to the tumor immune microenvironment. Dr. Ferris received his Ph.D. and M.D from the Johns Hopkins University School of Medicine.